Dr. Torres is a consultant for Gilead Sciences; Merck & Co., Inc.; Novartis; Astellas Pharma; Pfizer Inc.; Theravance Biopharma, Inc.; Genentech Inc.; and Vertex Pharmaceuticals, and received research grants from Merck & Co., Inc. and Vertex Pharmaceuticals. Dr. Kontoyiannis is a consultant for Merck & Co., Inc., a member of a speaker’s bureau of Merck & Co., Inc.; Gilead Sciences; and Pfizer Inc., and received research grants from Merck & Co., Inc.; Astellas Pharma; and Pfizer Inc. All other authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
The results of this study were presented in part at the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1–5, 2013; Washington, DC.
Author contributions: Dr. Torres designed the study, provided study patients, analyzed and interpreted the data, and wrote the manuscript; Dr. Mahale performed research, analyzed and interpreted the data, performed statistical analysis, designed tables and figures, and wrote the manuscript; Drs. Blechacz, Miller, Herlong, Kaseb, Fowler, Raad, and Kontoyiannis provided patients, analyzed and interpreted the data, and wrote the manuscript; and Dr. Jiang analyzed and interpreted the data, and performed statistical analyses.
The authors would like to thank Ann Sutton for editorial assistance.
AverhoffFMGlassNHoltzmanD. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis2012;55(Suppl 1):S10–15.
SmithBDMorganRLBeckettGA. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep2012;61(RR-4):1–32.
LeeMHYangHILuSN. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis2012;206:469–477.
MarkovicSDrozinaGVovkMFidler-JenkoM. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology1999;46:2925–2930.
FaggioliPDe PaschaleMTocciA. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica1997;82:38–42.
VentoSCainelliFLonghiMS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol2002;3:333–340.
HuangCFHuangJFChenWC. The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. Hepatol Int2013;7:180–187.
Peffault de LatourRLevyVAsselahT. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood2004;103:1618–1624.
Peffault de LatourRAsselahTLevyV. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant2005;36:709–713.
LjungmanPLocasciulliAde SoriaVG. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant2012;47:1217–1221.
AllisonRD. Increased risk of extra-hepatic cancer mortality among persons with chronic hepatitis C infection. Presented at: Annual meeting of the American College of Preventive Medicine; February 19-22, 2014; New Orleans, Louisiana.
MiraJARivero-JuarezALopez-CortesLF. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis2013;56:1646–1653.
TomblynMChillerTEinseleH. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant2009;15:1143–1238.
RamosCASalibaRMde PaduaL. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica2009;94:249–257.
TorresHAAdachiJARoachLR. Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way. Clin Infect Dis2012;54:740–742.
DavilaJAMorganROShaibY. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology2004;127:1372–1380.
GisbertJPGarcia-BueyLPajaresJMMoreno-OteroR. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology2003;125:1723–1732.
AntonelliAFerriCFallahiP. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid2007;17:447–451.
DonelliMGZucchettiMMunzoneE. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer1998;34:33–46.
LewisJHStineJG. Review article: prescribing medications in patients with cirrhosis—a practical guide. Aliment Pharmacol Ther2013;37:1132–1156.
MannsMPMcHutchisonJGGordonSC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958–965.
American Association for the Study of Liver Diseases Infectious Diseases Society of America. Recommendations for Testing Managing and Treating Hepatitis C.Available at: http://hcvguidelines.org/. Accessed March 28 2014.
AsciertoPAGogasHJGrobJJ. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol2013;85:149–161.
TalpazMHehlmannRQuintas-CardamaA. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia2013;27:803–812.
MahalePKontoyiannisDPChemalyRF. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol2012;57:1177–1185.
MorganRLBaackBSmithBD. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med2013;158:329–337.
MiyatakeHKobayashiYIwasakiY. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci2012;57:1092–1101.
BreitensteinSDimitroulisDPetrowskyH. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg2009;96:975–981.
SafdarA. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist2007;12(Suppl 2):2–6.
KlingemannHGGriggAPWilkie-BoydK. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected]. Blood1991;78:3306–3311.